AbbVie (XSGO:ABBVCL) Cyclically Adjusted Book per Share: CLP2,674.56 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSGO:ABBVCL AbbVie Inc XSGO:ABBVCL
76 GF Score
Price CLP171,590.00
GF Value CLP144,201.99
! 4 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted Book per Share?

AbbVie XSGO:ABBVCL 76 Cyclically Adjusted Book per Share is CLP2,674.56 as of Mar. 2026. GuruFocus rates XSGO:ABBVCL with a GF Score™ of 76/100 and a GF Value™ of CLP144,201.99. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

AbbVie's adjusted book value per share for the three months ended in Mar. 2026 was CLP-3,438.682. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is CLP2,674.56 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AbbVie's average Cyclically Adjusted Book Growth Rate was -11.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of AbbVie was 15.20% per year. The lowest was 3.20% per year. And the median was 8.70% per year.

As of today (2026-07-23), AbbVie's current stock price is CLP171590.00. AbbVie's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was CLP2,674.56. AbbVie's Cyclically Adjusted PB Ratio of today is 64.16.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AbbVie was 77.01. The lowest was 33.20. And the median was 46.77.


AbbVie  (XSGO:ABBVCL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=171590.00/2674.56
=64.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AbbVie was 77.01. The lowest was 33.20. And the median was 46.77.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


AbbVie Cyclically Adjusted Book per Share Related Terms


AbbVie Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted Book per Share Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3,654.98 2,643.43

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,302.23 3,485.05 2,712.36 2,643.43 2,674.56

XSGO:ABBVCL vs MRK, JNJ, AMGN: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PB Ratio falls into.


XSGO:ABBVCL
76GF Score
AbbVie Inc XSGO:ABBVCL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3438.682/330.2130*330.2130
=-3,438.682

Current CPI (Mar. 2026) = 330.2130.

AbbVie Quarterly Data

Book Value per Share CPI Adj_Book
201606 2,353.633 241.018 3,224.656
201609 2,658.899 241.428 3,636.707
201612 1,940.195 241.432 2,653.657
201703 2,079.043 243.801 2,815.932
201706 2,505.591 244.955 3,377.676
201709 2,622.704 246.819 3,508.850
201712 2,034.242 246.524 2,724.818
201803 1,352.682 249.554 1,789.886
201806 -1,421.035 251.989 -1,862.162
201809 -1,320.867 252.439 -1,727.813
201812 -3,908.394 251.233 -5,137.074
201903 -3,544.923 254.202 -4,604.919
201906 -4,003.807 256.143 -5,161.606
201909 -3,998.187 256.759 -5,141.994
201912 -4,228.580 256.974 -5,433.749
202003 -4,219.650 258.115 -5,398.304
202006 6,634.905 257.797 8,498.671
202009 6,688.758 260.280 8,485.918
202012 5,410.400 260.474 6,858.974
202103 5,638.037 264.877 7,028.746
202106 5,182.883 271.696 6,299.155
202109 6,019.748 274.310 7,246.542
202112 7,404.698 278.802 8,770.122
202203 7,357.924 287.504 8,450.951
202206 7,188.310 296.311 8,010.750
202209 8,362.783 296.808 9,303.993
202212 8,508.506 296.797 9,466.468
202303 6,075.736 301.836 6,646.944
202306 5,828.708 305.109 6,308.287
202309 6,073.454 307.789 6,515.936
202312 5,137.675 306.746 5,530.723
202403 4,397.235 312.332 4,648.977
202406 3,561.420 314.175 3,743.223
202409 3,160.483 315.301 3,309.956
202412 1,854.549 315.605 1,940.388
202503 749.541 319.799 773.949
202506 -97.111 322.561 -99.415
202509 -1,434.675 324.800 -1,458.585
202512 -1,690.503 324.054 -1,722.633
202603 -3,438.682 330.213 -3,438.682

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of CLP2,674.56 mean?
AbbVie (XSGO:ABBVCL) has a Cyclically Adjusted Book per Share of CLP2,674.56 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's Cyclically Adjusted Book per Share too high?
AbbVie's current Cyclically Adjusted Book per Share is CLP2,674.56. Overall, AbbVie has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cyclically Adjusted Book per Share compare to MRK and JNJ?
AbbVie's Cyclically Adjusted Book per Share of CLP2,674.56 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current Cyclically Adjusted Book per Share is CLP2,674.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
AbbVie (XSGO:ABBVCL) has a current Cyclically Adjusted Book per Share of CLP2,674.56. The stock's GF Value™ is CLP144,201.99, compared to a current price of CLP171,590.00 — trading 19% above its estimated fair value. The current Cyclically Adjusted Book per Share is CLP2,674.56. AbbVie's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For AbbVie (XSGO:ABBVCL), the current Cyclically Adjusted Book per Share is CLP2,674.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (XSGO:ABBVCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CLP171,590.00 is trading 19% above its estimated GF Value™ of CLP144,201.99.

Key valuation signals for XSGO:ABBVCL:

  • Cyclically Adjusted Book per Share: CLP2,674.56
  • GF Value™: CLP144,201.99 vs. price of CLP171,590.00 (19% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the XSGO:ABBVCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
76GF Score

Get the complete analysis for XSGO:ABBVCL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CLP171,590.00
Price
CLP144,201.99
GF Value